Form 4: Ionis Pharma Exec Reports Stock Transactions

Ionis Pharmaceuticals' EVP, CLO & General Counsel, Patrick R. O'Neil, reported the vesting of restricted stock units, a tax-related stock sale, and new grants of performance and restricted stock units.

Summary

• Patrick R. O'Neil, EVP CLO & General Counsel of Ionis Pharmaceuticals Inc., reported multiple transactions involving the company's common stock and derivative securities.
• On January 15, 2026, 21,473 shares of common stock were acquired due to the vesting and release of Restricted Stock Unit (RSU) awards.
• On January 16, 2026, 9,191 shares of common stock were sold at a weighted average price of $75.84 per share to cover required tax withholding obligations.
• A grant of 25,800 Performance Restricted Stock Units (PRSUs) was made on January 15, 2026, which may vest based on the Issuer's relative total shareholder return over a three-year performance period.
• An additional grant of 9,675 Restricted Stock Units (RSUs) was made on January 15, 2026, with these units vesting in four equal annual installments.
• Following these transactions, Mr. O'Neil beneficially owns 66,171 shares of common stock, 90,601 PRSUs, and 48,926 RSUs.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions, including equity grants and a tax-related stock sale, which are standard components of executive compensation and do not inherently indicate a positive or negative sentiment about the company's performance or prospects.

Positives

• The grant of 25,800 Performance Restricted Stock Units (PRSUs) aligns executive compensation with future company performance and shareholder returns over a three-year period.
• The grant of 9,675 Restricted Stock Units (RSUs) provides ongoing equity incentives, vesting in four equal annual installments.
• The acquisition of 21,473 shares of common stock through RSU vesting demonstrates the realization of prior equity awards and continued equity ownership.

Negatives

• The sale of 9,191 shares of common stock, even if for tax purposes, reduces the executive's direct equity holding in the company.

Future Outlook

The future outlook for the reporting person's equity holdings includes the potential vesting of 25,800 Performance Restricted Stock Units (PRSUs) at the end of a three-year performance period (January 15, 2029), contingent on the company's relative total shareholder return. Additionally, 9,675 Restricted Stock Units (RSUs) are scheduled to vest in four equal annual installments, starting from January 15, 2027.

Industry Context

This Form 4 filing details routine insider transactions for an executive at a publicly traded pharmaceutical company. Such transactions, involving equity grants and tax-related sales, are common in the biotech and pharmaceutical industry as part of executive compensation packages designed to align management interests with shareholder value.

Stakeholder Impact

• Shareholders: The grants of PRSUs and RSUs align executive incentives with shareholder value creation, while the tax-related sale is a routine event with minimal direct impact.
• Employees: The equity grants reflect standard compensation practices for executives, potentially setting a precedent for broader employee incentive programs.

Next Steps

• Monitoring the vesting of 25,800 Performance Restricted Stock Units (PRSUs) based on the company's relative total shareholder return over the next three years.
• Tracking the annual vesting of 9,675 Restricted Stock Units (RSUs) in four equal installments, starting from January 15, 2027.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, Performance Restricted Stock Units, Equity Incentive Plan, Stock Sale, Tax Withholding